Prestige Consumer Healthcare In vs Redhill Biopharma Ltd. — Valuation Comparison 2026
Access all valuation models for PBH vs RDHL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →PBH scores higher with a 8.1/10 quality rating vs RDHL's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Prestige Consumer Healthcare In (PBH) and Redhill Biopharma Ltd. (RDHL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
PBH currently trades at $48.47 with a QOC of 8.1/10, while RDHL trades at $1.00 with a QOC of 5.0/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).